• Vaccine Name: ESAT-6-gpi DNA vaccine combined with B16F10-ESAT-6-gpi/IL-21 vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0007603
• Type: DNA and tumor vaccine
• Status: Research
• Antigen: ESAT-6
• Immunization Route: Intramuscular injection (i.m.)
• Description: Mice immunized with the glycosylphosphatidylinositol (GPI) anchored 6-kDa early-secreted antigenic target (ESAT-6) DNA vaccine (ESAT-6-gpi) and the tumour vaccine B16F10-ESAT-6-gpi/IL-21 might significantly enhance immune responses and antimelanoma efficacy. Our experimental results indicated that the anti-ESAT-6 antibody induced by the DNA vaccine ESAT-6-gpi bound ESAT-6 to the surface of tumour vaccine to activate a complement classical pathway and resulted in the B16F10 tumour cell lysis and apoptosis, which served as a potential trigger for breaking melanomatous immune tolerance to elicit an initiation of natural antimelanoma immunity (He et al., 2013).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Immune Response: DNA vaccine ESAT-6-gpi priming and the tumour vaccine B16F10-ESAT-6-gpi/IL-21 boosting induced strong antimelanoma immunity that inhibited melanomatous growth; ESAT-6 was successfully anchored on the B16F10 cell membrane via GPI, IL-21 expression was in the B16F10-ESAT-6-gpi/IL-21 cells, but no IL-21 expression was in the B16F10/mock cells nor in the B16F10-ESAT-6-gpi cells, serum IFN-c level in the mice immunized with the DNA vaccine ESAT-6-gpi was significantly increased in contrast to that in the mice immunized with the pIRES mock plasmid (He et al., 2013).